カテゴリ： GlobalData, アメリカ, 企業調査

Bristol-Myers Squibb Co (BMY)-製薬・医療分野：企業M&A・提携分析

◆英語タイトル：Bristol-Myers Squibb Co (BMY) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA8012200
◆発行会社（調査会社）：GlobalData
◆発行日：2017年12月14日
◆ページ数：337
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：アメリカ
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single UserUSD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Bristol-Myers Squibb Company (BMS) is specialty biopharmaceutical company that carries out the discovery, development, licensing, manufacturing, marketing, distribution and sale of medicines to patients with serious diseases. Its primary focus is in cancer, cardiovascular, immunoscience and virology (including hepatitis B, hepatitis C and HIV infection) therapeutic classes. The company offers its products across the world primarily to retail pharmacies, wholesalers, hospitals, medical professionals and government entities. BMS provides its products in the US, Europe, Japan and other countries. The company’s research activities focus on the discovery and development of novel medicines that address serious disease in areas of significant unmet medical need. BMS is headquartered in New York City, New York, the US.

Bristol-Myers Squibb Co (BMY) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 9
List of Figures 12
Bristol-Myers Squibb Co, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 13
Bristol-Myers Squibb Co, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 14
Bristol-Myers Squibb Co, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 15
Bristol-Myers Squibb Co, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 16
Bristol-Myers Squibb Co, Medical Devices Deals, 2011 to YTD 2017 18
Bristol-Myers Squibb Co, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 19
Bristol-Myers Squibb Co, Pharmaceuticals & Healthcare, Deal Details 31
Asset Purchase 31
AstraZeneca And BMS Acquires Exenatide From Eli Lilly Japan 31
Venture Financing 33
Blade Therapeutics Raises Additional USD18.3 Million in Series B Financing 33
Cardior Pharma Raises USD16.3 Million in Series A Financing 35
Grail Raises USD914 Million in First Tranche of Series B Financing 37
IFM Therapeutics Raises USD27 Million in Series A Financing Round 39
Blade Therapeutics Raises USD27 Million in Series B Financing 40
IFM Therapeutics Raises Funds in Seed Financing Round 42
Padlock Therapeutics Raises USD23 Million in Extended Series A Financing 43
Flexus Biosciences Raises USD25 Million in Series B Venture Financing 44
iPierian Raises USD1 Million in Venture Financing 45
Padlock Therapeutics Raises Funds through Series A Financing 46
Flexus Biosciences Raises USD13 Million in Series A Venture Financing 47
iPierian Raises US$30 Million In Series A Venture Financing 48
Cormorant Pharma Raises US$2.6 Million In Venture Financing 50
Cardioxyl Pharma Raises US$28 Million In Series B Financing 51
Partnerships 52
AbbVie and Bristol-Myers Squibb Enter into Agreement 52
Bristol-Myers Squibb and Daiichi Sankyo Enter into Agreement 53
Bristol-Myers Squibb and Clovis Oncology Enter into Agreement 54
Bristol-Myers Squibb Enters into Partnership with Novartis 55
Bristol-Myers Squibb and Qiagen Enter into Agreement 56
Advaxis and Bristol-Myers Squibb Enter into Agreement 57
Array BioPharma and Bristol-Myers Squibb Enter into Research Agreement 58
Bristol-Myers Squibb Enters into Research Agreement with Transgene 59
Bristol-Myers Squibb Enters into Agreement with Nordic Bioscience 60
Bristol-Myers Squibb Enters into Agreement with Apexigen 61
Bristol-Myers Squibb and Incyte Enter into Agreement 62
Bristol-Myers Squibb Enters into Agreement with Foundation Medicine 63
Parker Institute for Cancer Immunotherapy, Bristol-Myers Squibb and Cancer Research Institute Enter into Research Partnership 64
Exelixis Enters into Agreement with Bristol-Myers Squibb 65
Bristol-Myers Squibb Enters into Research Agreement with GeneCentric Diagnostics 66
Janssen Biotech Enters into Partnership with Bristol-Myers 67
Bristol-Myers Squibb and Calithera Biosciences Expand Agreement 68
Target Pharma Extends Agreement with Bristol-Myers Squibb 69
Bristol-Myers Squibb Company Enters into Agreement with John Hopkins University 70
Bristol-Myers Squibb Expands Agreement with Infinity Pharma 71
Bristol-Myers Squibb Company Enters into Agreement with Nektar Therapeutics 72
Bristol-Myers Squibb Enters into Co-Development Agreement with Institut Curie 73
Bristol-Myers Squibb Enters into Research Agreement with Janssen Biotech 74
AbbVie and Bristol-Myers Squibb Enter into Agreement 75
GreenPeptide Enters into Agreement with Bristol-Myers Squibb 76
Bristol-Myers Squibb Enters into Agreement with PsiOxus Therapeutics 77
Bristol-Myers Squibb and University of Texas MD Anderson Enter into Research Agreement 78
Bristol-Myers Squibb Enters into Research Agreement with Dana-Farber Cancer Institute 79
Oncodesign Enters into Agreement with Bristol-Myers Squibb 80
Seattle Genetics and Bristol-Myers Squibb Enter into Clinical Trial Agreement 81
Bristol-Myers Squibb Enters into Agreement with Ohio State University Comprehensive Cancer Center 82
IFM Therapeutics to Enter into Research Agreement with University of Michigan 83
Neon Therapeutics Enters into Agreement with Bristol-Myers Squibb 84
Bristol-Myers Squibb Enters into Research Agreement with UCLA 85
Bristol-Myers Squibb Enters into Research Agreement with Princeton University 86
Bristol-Myers Squibb Enters into Research Agreement with NCCN 87
Bristol-Myers Squibb Enters into Research Agreement with Sidney Kimmel Comprehensive Cancer Center 88
Bristol-Myers Squibb Enters into Research Agreement with Medical University of South Carolina 89
Bristol-Myers Squibb Enters into Agreement with uniQure 90
Rigel Enters into R&D Agreement with Bristol-Myers Squibb for TGF Beta Receptor Kinase Inhibitors 91
Bristol-Myers Squibb Enters into Agreement with Eli Lilly 92
Bristol-Myers Squibb and Seattle Genetics Enter into Agreement 93
Bristol-Myers Squibb Enters into Agreement with Five Prime Therapeutics for Opdivo and FPA008 94
OliPass Enters into Co-Development Agreement with Bristol-Myers Squibb 96
Bristol-Myers Squibb Enters into Agreement with Celgene 97
Bristol-Myers Squibb Forms Joint Venture with Allied Minds 98
Bristol-Myers Squibb Enters into Co-Development Agreement with Ono Pharma 99
Syngene International Extends R&D Agreement with Bristol-Myers Squibb 101
Pierre Fabre Enters into Co-Promotion Agreement with Bristol-Myers Squibb for Orencia 102
Evotec Extends Agreement with Padlock Therapeutics 103
Evotec Enters into Agreement with Padlock Therapeutics 104
Immuneering Enters Into Agreement With Bristol-Myers Squibb For New Medicines 105
AstraZeneca Enters Into Agreement With Bristol-Myers To Commercialize Dapagliflozin In Japan 106
Bristol-Myers Squibb And Samsung BioLogics Enter Into Agreement For Antibody Cancer Drug 107
Bristol-Myers Squibb Expands Co-Development Agreement With Simcere Pharma For Orencia 108
Ambrx Enters Into Co-Development Agreement With Bristol-Myers Squibb 110
Santaris Pharma Enters Into Agreement With Bristol-Myers Squibb For RNA-Targeted Medicines 111
Merck Serono Enters Into Co-Promotion Agreement With Bristol-Myers Squibb For Glucophage 112
PeptiDream Extends Discovery Agreement With Bristol-Myers Squibb 113
Valeant Pharma Enters into Option Agreement with Bristol-Myers Squibb 114
Vanderbilt University Enters Into Agreement With Bristol-Myers Squibb To Develop Drugs For Parkinson’s Disease 115
Prosetta Enters Into Co-Development Agreement With Bristol-Myers Squibb For Antiviral Drugs 116
Bristol-Myers Squibb Enters Into Co-Development Agreement With Emory University 117
Scripps Research Institute Enters Into Research Agreement With Bristol-Myers Squibb 118
Bristol-Myers Squibb Enters Into Co-Development Agreement With Tsinghua University 119
Bristol-Myers Squibb Enters Into Co-Development Agreement With Duke Translational Medicine Institute 120
Ensemble Therapeutics Extends Co-Development Agreement With Bristol-Myers Squibb 121
Bristol-Myers Squibb Enters Into Research Agreement With Gladstone Institutes 122
NeurOp Extends Drug Discovery Agreement With Bristol-Myers Squibb 123
Bristol-Myers Squibb Expands Co-Development Agreement With Simcere Pharma For BMS-795311 124
Dako Enters Into Co-Development Agreement With Bristol-Myers 125
Tranzyme Pharma Extends Co-Development Agreement With Bristol-Myers Squibb 126
Bristol-Myers Squibb Expands Co-Development Agreement With Ono Pharma 127
Bristol-Myers Squibb Enters Into Co-Development Agreement With Ono Pharma For ORENCIA 129
BAC Enters Into Co-Development Agreement With Bristol-Myers Squibb 131
GNS Healthcare Enters Into Co-Development Agreement With Bristol-Myers Squibb 132
Bristol-Myers Squibb Enters Into Co-Marketing Agreement With Matrix Labs 133
Hoffmann-La Roche Enters Into Co-Development Agreement With Bristol-Myers Squibb 134
Licensing Agreements 135
Ayala Pharma Enters into Licensing Agreement with Bristol-Myers Squibb 135
Bristol-Myers Squibb and Halozyme Therapeutics to Enter into License Agreement 136
Biogen Enters into Licensing Agreement with Bristol-Myers Squibb 137
Roche to Enter into Licensing Agreement with Bristol-Myers Squibb 138
Merck Enters into Licensing Agreement with Bristol-Myers Squibb and Ono Pharma 139
Bristol-Myers Squibb to Enter into Licensing Agreement with PsiOxus Therapeutics 140
Bristol-Myers Squibb Enters into Licensing Agreement with Enterome 141
Bristol-Myers Squibb Enters into Licensing Agreement with Nitto Denko 142
Mylan Enters into Licensing Agreement with Medicines Patent Pool and Bristol-Myers Squibb Company for Daclatasvir 143
Biohaven Pharma Enters into Licensing Agreement with Bristol-Myers Squibb 144
Mylan Enters into Licensing Agreement with Medicines Patent Pool and Bristol-Myers Squibb Company 145
Eiger BioPharmaceuticals Enters into Licensing Agreement with Bristol-Myers Squibb 146
Bristol-Myers Squibb and Pfizer Enter into Licensing Agreement with Portola Pharma 147
Bristol-Myers Squibb Enters into Licensing Agreement with Kyorin Pharma 149
Zai Lab Enters into Licensing Agreement with Bristol-Myers Squibb 150
Bristol-Myers Squibb Enters into Option for Licensing Agreement with Bavarian Nordic 151
Bristol-Myers Squibb Enters into Licensing Agreement with California Institute for Biomedical Research 152
Cipla Enter into Licensing Agreement with Medicines Patent Pool and Bristol-Myers Squibb Company 153
Bristol-Myers Squibb Extends Licensing Agreement with CytomX Therapeutics 154
Five Prime Therapeutics Expand Licensing Agreement with Bristol-Myers Squibb 156
Medicines Patent Pool Extends Licensing Agreement With Bristol-Myers Squibb 158
Reckitt Benckiser Amends Licensing Agreement With Bristol-Myers Squibb For OTC Brands 159
Sanofi Enters into Licensing Agreement with Bristol-Myers Squibb 161
Bristol-Myers Squibb Enters into License Agreement with Ambrx 162
Lexicon Pharma Enters into Licensing Agreement with Bristol-Myers Squibb 163
MPP, Bristol-Myers Squibb and Laurus Labs Enter into Licensing Agreement For Daclatasvir 164
Cipla, Emcure Pharma, Hetero Drugs, Natco Pharma and Aurobindo Pharma Enter into Licensing Agreement with Medicines Patent Pool and Bristol-Myers Squibb 165
Medicines Patent Pool Enters into Licensing Agreement with Bristol-Myers Squibb For Daclatasvir 167
Bristol-Myers Squibb Enters into Licensing Agreement with Five Prime Therapeutics 168
Bristol-Myers Squibb Enters into Licensing Agreement with Kyorin Pharma 170
Bristol-Myers Squibb Enters into Licensing Agreement with QIMR Berghofer Medical Research Institute 171
Genmab Enters into Licensing Agreement with Bristol-Myers Squibb 172
Padlock Therapeutics Enters into Licensing Agreement with GlaxoSmithKline 173
Bristol-Myers Squibb Enters into Licensing Agreement with Novo Nordisk 174
Bristol-Myers Squibb Enters into Licensing Agreement with R-Pharm 175
Padlock Therapeutics Enters into Licensing Agreement with Scripps Research Institute 176
Bristol-Myers Squibb Enters Into Licensing Agreement With Kyowa Hakko Kirin For Coniel In China 177
PeptiDream Enters Into Licensing Agreement With Bristol-Myers Squibb For Peptide Discovery Platform System 178
PeptiDream Expands Agreement With Bristol-Myers Squibb For Drug Discovery 179
Medicines Company Enters Into Licensing Agreement With Bristol-Myers Squibb For Recothrom 180
Biocon Enters Into Option For Licensing Agreement With Bristol-Myers Squibb 182
Chiromics Enters Into Licensing Agreement With Bristol-Myers Squibb For Chemical Compounds 183
University Of Montreal Enters Into Licensing Agreement With Bristol-Myers Squibb 184
Bristol-Myers Squibb Enters Into Licensing Agreement With Vical For Antibodies 186
Summit Enters Into Licensing Agreement With Bristol-Myers Squibb For Seglin Technology 188
Genmab Enters Into Licensing Agreement With Cormorant Pharma For HuMax-IL8 189
Bristol-Myers Squibb Enters Into Licensing Agreement With Gilead Sciences 190
Bristol-Myers Squibb Enters Into Licensing Agreement With Innate Pharma For IPH2102 191
KineMed Extends Licensing Agreement With Bristol-Myers Squibb 193
iPierian Enters Into Licensing Agreement With Kyoto University 194
Kyoto University And iPS Academia Enter Into Licensing Agreement With iPierian 195
Equity Offering 196
uniQure Raises USD38 Million in Private Placement of Shares 196
Panmira Pharmaceuticals Spin Out from Amira Pharmaceuticals 197
Inhibitex Files Registration Statement For Public Offering Of Securities For US$130 Million 198
Inhibitex Completes An Underwritten Public Offering For US$54.1 Million 199
Debt Offering 201
Bristol-Myers Squibb Raises USD750 Million in Public Offering of 1.6% Notes Due 2019 201
Bristol-Myers Squibb Raises USD750 Million in Public Offering of 3.25% Notes Due 2027 203
Bristol-Myers Squibb Raises USD628 Million in Public Offering of 1.75% Notes Due 2035 205
Bristol-Myers Squibb Raises USD628 Million in Public Offering of 1% Notes Due 2025 206
Bristol-Myers Squibb Completes Public Offering Of Notes Due 2019 For US$500 Million 207
Bristol-Myers Squibb Completes Public Offering Of Notes Due 2023 For US$500 Million 209
Bristol-Myers Squibb Completes Public Offering Of Notes Due 2044 For US$500 Million 211
Bristol-Myers Squibb Completes Public Offering Of Senior Unsecured Notes Due 2017 For US$750 Million 213
Bristol-Myers Squibb Completes Public Offering Of 2% Senior Unsecured Notes Due 2022 For US$750 Million 215
Bristol-Myers Squibb Completes Public Offering Of 3.25% Senior Unsecured Notes Due 2042 For US$500 Million 217
Asset Transactions 219
Seattle Genetics to Acquire Pharma Manufacturing Facility from Bristol-Myers Squibb 219
SK Biotek to Acquire API Manufacturing Facility from Bristol-Myers Squibb 220
Reckitt Benckiser Exercises Option to Acquire OTC Products of Bristol-Myers Squibb for USD317 Million 221
ViiV Healthcare Acquires HIV R&D Assets of Bristol-Myers Squibb for up to USD835 Million 222
ViiV Healthcare Acquires HIV Research Assets of Bristol-Myers Squibb for USD620 Million 223
R-Pharm US Acquires Rights to IXEMPRA from Bristol-Myers Squibb 224
PharmaSwiss Acquires Trademarks and Intellectual Property of Certain Products from Bristol-Myers Squibb for USD61 Million 225
Bristol-Myers Squibb Reportedly To Sell Plavix And Avapro For US$750 Million 226
Emcure Pharma Acquires Rights of BiCNU Injection from Bristol-Myers Squibb 227
Synergy Pharma Acquires FV-100 From Bristol-Myers Squibb 228
Paladin Labs Completes Acquisition Of Tempra From Bristol-Myers Squibb 229
Acquisition 230
Bristol-Myers Squibb Acquires IFM Therapeutics 230
Bristol-Myers Squibb Acquires Cormorant Pharma 231
Bristol-Myers Squibb Acquires Padlock Therapeutic 232
Bristol-Myers Squibb Acquires Cardioxyl Pharma for up to USD2.1 Billion 233
Bristol-Myers Squibb Enters into Option to Acquire Promedior and PRM-151 for up to USD1.25 Billion 234
Bristol-Myers Squibb Acquires Flexus Biosciences for up to USD1.25 Billion 236
Bristol-Myers Squibb Enters into Option to Acquire Galecto Biotech and TD-139 237
Pfizer May Acquire Bristol-Myers Squibb 238
Bristol-Myers Squibb Acquires iPierian 239
AstraZeneca Completes Acquisition Of Remaining 50% Interest In Diabetes Joint Venture From Bristol-Myers Squibb For US$4.3 Billion 241
Bristol-Myers Rumored To Acquire Biogen Idec 243
Bristol-Myers Squibb Completes Acquisition Of Amylin Pharma For US$5.3 Billion 244
Bristol-Myers Squibb Completes Acquisition Of Inhibitex, Hepatitis C Drug Developer, For US$2.5 Billion 246
Bristol-Myers Squibb Acquires Amira Pharma For US$475 Million 249
Bristol-Myers Squibb Co – Key Competitors 251
Bristol-Myers Squibb Co – Key Employees 252
Bristol-Myers Squibb Co – Locations And Subsidiaries 254
Head Office 254
Other Locations & Subsidiaries 254
Joint Venture 260
Recent Developments 261
Strategy And Business Planning 261
Nov 01, 2017: Bristol-Myers Squibb, BioLabs Announce Founding Sponsorship in Support of Promising Biotech Companies in New York 261
Dec 13, 2016: Bristol-Myers Squibb Strengthens Capabilities with Evolution of its U.S. Geographic Footprint 262
May 17, 2016: Bristol-Myers Squibb Opens Expanded Biologics Facility 263
Mar 16, 2016: Allied-Bristol Life Sciences Launches ißeCa Therapeutics from NYU School of Medicine to Develop Novel Cancer Therapeutics Targeting the Wnt Pathway 264
Financial Announcements 265
Oct 26, 2017: Bristol-Myers Squibb Reports Third Quarter Financial Results 265
Jul 27, 2017: Bristol-Myers Squibb Reports Second Quarter Financial Results 267
Apr 27, 2017: Bristol-Myers Squibb Reports First Quarter Financial Results 270
Jan 26, 2017: Bristol-Myers Squibb Reports Fourth Quarter and Full Year 2016 Financial Results 273
Oct 27, 2016: Bristol-Myers Squibb Reports Third Quarter Financial Results 276
Jul 28, 2016: Bristol-Myers Squibb Reports Second Quarter Financial Results 280
Jan 28, 2016: Bristol-Myers Squibb Reports Fourth Quarter and Full Year 2015 Financial Results 283
Corporate Communications 286
Oct 09, 2017: Bristol-Myers Squibb Appoints Saurabh Saha, M.D., Ph.D., as Senior Vice President, Global Head of Translational Medicine 286
Sep 13, 2017: Bristol-Myers Squibb Names Karen Vousden, Ph.D. to Board of Directors 287
Apr 12, 2017: NICE’s draft guidance ignores recommendation of Opdivo to treat cancer, Bristol-Myers Squibb says 288
Mar 08, 2017: Bristol-Myers Squibb Appoints Dr. Thomas J. Lynch, Jr., Executive Vice President and Chief Scientific Officer 289
Feb 21, 2017: Bristol-Myers Squibb Appoints Three New Independent Directors 291
Dec 21, 2016: Giovanni Caforio Named Chairman of Bristol-Myers Squibb’s Board of Directors 292
Apr 13, 2016: Stand Up To Cancer Launches “Catalyst,” a New Research Program Supported by Industry 293
Mar 03, 2016: Bristol-Myers Squibb Names Peter J. Arduini to Board of Directors 294
Feb 03, 2016: Bonnie J. Addario Lung Cancer Foundation Honors Bristol-Myers Squibb for Improving and Advancing Breakthrough Treatments for Lung Cancer 295
Government and Public Interest 296
Oct 26, 2017: Study to test combination therapy for breast cancer 296
Sep 08, 2017: Major breakthroughs spell hope for melanoma patients 297
May 25, 2016: Allied Minds announces successful completion of ABLS II drug candidate feasibility programme and approval of up to $15 million to fund further drug development 298
Apr 21, 2016: New Molecule-Building Method from TSRI Opens Up Vast Realm of Chemistry for Pharma and Other Industries 299
Apr 17, 2016: CHAI Announces Partnership with Governments in Six Low- and Middle-Income Countries to Initiate and Expand Hepatitis C Treatment Programs 301
Product News 302
12/05/2016: CytomX Announces Fourth Target Selection by Bristol-Myers Squibb Under Strategic Oncology Collaboration 302
12/05/2016: Innate Pharma Presented Clinical Data for Lirilumab at ASH Annual Meeting 303
11/12/2016: Interim Phase 1/2 Data Show Encouraging Clinical Benefit for Lirilumab in Combination With Opdivo (nivolumab) in Patients With Advanced Platinum Refractory Squamous Cell Carcinoma of the Head and Neck 305
11/08/2016: Preliminary Phase 1/2 efficacy data of Lirilumab in combination with Opdivo (Nivolumab) in patients with advanced platinum refractory squamous cell carcinoma of the head and neck to be presented during SITC meeting 307
Oct 12, 2017: 10 SU2C Catalyst Clinical Trials Launched 308
10/09/2016: Safety Data for Lirilumab in Combination with Nivolumab or Ipilimumab Announced at ESMO 2016 Congress 310
07/27/2016: Combining Ipilimumab with local treatments improved survival for patients with melanoma 312
Jul 18, 2016: Publication of HPTN 052 final results 313
06/15/2016: PeptiDream Achieves Milestone for Initiation of Clinical Development for Bristol-Myers Squibb First Collaboration Product Candidate 314
06/14/2017: Bristol-Myers Squibb To Present on BMS-986165 at the Annual European Congress of Rheumatology (EULAR 2017) 315
06/08/2016: Bristol-Myers Squibb Announces Data on BMS-986142 at the Annual European Congress of Rheumatology (EULAR 2016) 316
06/04/2017: Five Prime Therapeutics Presents Initial Clinical Trial Data from Phase 1/2 trial of Cabiralizumab in Pigmented Villonodular Synovitis (PVNS) at 2017 ASCO Annual Meeting 317
06/03/2017: Anti-LAG-3 (BMS-986016) in Combination with Opdivo (nivolumab) Showed Activity in Patients with Melanoma Who Were Relapsed or Refractory to Anti-PD-1/PD-L1 Therapy 318
04/20/2017: Five Prime to Present Clinical Data on cabiralizumab at 2017 ASCO Annual Meeting 320
03/13/2017: Expansion Of Phase I/II Trial Evaluating Lirilumab In Combination With Opdivo (Nivolumab) In Patients With Advanced Solid Tumors 321
01/20/2016: CytomX Announces Third Target Selection by Bristol-Myers Squibb, Triggering Milestone 322
Product Approvals 323
Jan 24, 2017: European Commission Grants Orphan Drug Designation to Cabiralizumab (FPA008) for Pigmented Villonodular Synovitis 323
Jan 13, 2016: Five Prime Therapeutics Receives FDA Orphan Drug Designation for FPA008 in Pigmented Villonodular Synovitis 324
Clinical Trials 325
Apr 10, 2017: Five Prime Therapeutics Announces Completion of Enrollment for the Phase 2 Part of the Ongoing Trial of Cabiralizumab for the Treatment of Pigmented Villonodular Synovitis 325
Apr 03, 2017: Five Prime Presents Preclinical Research Data on CSF-1R and PD-1 Blockade at the 2017 AACR Annual Meeting 326
Feb 06, 2017: INNATE PHARMA announces top-line results from EffiKIR trial evaluating the efficacy of lirilumab 327
Oct 04, 2016: Five Prime Therapeutics Advances into Phase 1b Portion of Trial Evaluating the Immunotherapy Combination of Cabiralizumab (FPA008) and OPDIVO (nivolumab) in Multiple Tumor Types 328
Sep 29, 2016: Seventh Data And Safety Monitoring Board Meeting Of The Effikir Trial Recommends Continuation Without Modification 329
Sep 28, 2016: Safety Data for Lirilumab in Combination with Nivolumab or Ipilimumab to be Presented at the ESMO 2016 Congress 330
Jul 13, 2016: Immunotherapy benefits relapsed stem cell transplant recipients 331
Jul 11, 2016: Initiation of Drug Development for Oncology Using Nitto’s Proprietary DDS Platform 332
Mar 16, 2016: Sixth Data And Safety Monitoring Board Meeting Of The Effikir Trial Recommends Continuation Without Modification 333
Other Significant Developments 334
May 31, 2017: PeptiDream Announces 5 th Milestone from Macrocyclic Peptide Drug Discovery Alliance with Bristol-Myers Squibb 334
Feb 27, 2017: Bristol-Myers Squibb Expands International Immuno-Oncology Network (II-ON) With Addition of Columbia University Medical Center and Peter MacCallum Cancer Centre 335
Jun 01, 2016: Bristol-Myers Squibb Executive to Discuss New Data-Driven Approach to Driving Sales Excellence at 2016 LTEN Conference 336
Appendix 337
Methodology 337
About GlobalData 337
Contact Us 337
Disclaimer 337

List of Tables
Bristol-Myers Squibb Co, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Bristol-Myers Squibb Co, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 13
Bristol-Myers Squibb Co, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 14
Bristol-Myers Squibb Co, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 15
Bristol-Myers Squibb Co, Deals By Therapy Area, 2011 to YTD 2017 16
Bristol-Myers Squibb Co, Medical Devices Deals, 2011 to YTD 2017 18
Bristol-Myers Squibb Co, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 19
AstraZeneca And BMS Acquires Exenatide From Eli Lilly Japan 31
Blade Therapeutics Raises Additional USD18.3 Million in Series B Financing 33
Cardior Pharma Raises USD16.3 Million in Series A Financing 35
Grail Raises USD914 Million in First Tranche of Series B Financing 37
IFM Therapeutics Raises USD27 Million in Series A Financing Round 39
Blade Therapeutics Raises USD27 Million in Series B Financing 40
IFM Therapeutics Raises Funds in Seed Financing Round 42
Padlock Therapeutics Raises USD23 Million in Extended Series A Financing 43
Flexus Biosciences Raises USD25 Million in Series B Venture Financing 44
iPierian Raises USD1 Million in Venture Financing 45
Padlock Therapeutics Raises Funds through Series A Financing 46
Flexus Biosciences Raises USD13 Million in Series A Venture Financing 47
iPierian Raises US$30 Million In Series A Venture Financing 48
Cormorant Pharma Raises US$2.6 Million In Venture Financing 50
Cardioxyl Pharma Raises US$28 Million In Series B Financing 51
AbbVie and Bristol-Myers Squibb Enter into Agreement 52
Bristol-Myers Squibb and Daiichi Sankyo Enter into Agreement 53
Bristol-Myers Squibb and Clovis Oncology Enter into Agreement 54
Bristol-Myers Squibb Enters into Partnership with Novartis 55
Bristol-Myers Squibb and Qiagen Enter into Agreement 56
Advaxis and Bristol-Myers Squibb Enter into Agreement 57
Array BioPharma and Bristol-Myers Squibb Enter into Research Agreement 58
Bristol-Myers Squibb Enters into Research Agreement with Transgene 59
Bristol-Myers Squibb Enters into Agreement with Nordic Bioscience 60
Bristol-Myers Squibb Enters into Agreement with Apexigen 61
Bristol-Myers Squibb and Incyte Enter into Agreement 62
Bristol-Myers Squibb Enters into Agreement with Foundation Medicine 63
Parker Institute for Cancer Immunotherapy, Bristol-Myers Squibb and Cancer Research Institute Enter into Research Partnership 64
Exelixis Enters into Agreement with Bristol-Myers Squibb 65
Bristol-Myers Squibb Enters into Research Agreement with GeneCentric Diagnostics 66
Janssen Biotech Enters into Partnership with Bristol-Myers 67
Bristol-Myers Squibb and Calithera Biosciences Expand Agreement 68
Target Pharma Extends Agreement with Bristol-Myers Squibb 69
Bristol-Myers Squibb Company Enters into Agreement with John Hopkins University 70
Bristol-Myers Squibb Expands Agreement with Infinity Pharma 71
Bristol-Myers Squibb Company Enters into Agreement with Nektar Therapeutics 72
Bristol-Myers Squibb Enters into Co-Development Agreement with Institut Curie 73
Bristol-Myers Squibb Enters into Research Agreement with Janssen Biotech 74
AbbVie and Bristol-Myers Squibb Enter into Agreement 75
GreenPeptide Enters into Agreement with Bristol-Myers Squibb 76
Bristol-Myers Squibb Enters into Agreement with PsiOxus Therapeutics 77
Bristol-Myers Squibb and University of Texas MD Anderson Enter into Research Agreement 78
Bristol-Myers Squibb Enters into Research Agreement with Dana-Farber Cancer Institute 79
Oncodesign Enters into Agreement with Bristol-Myers Squibb 80
Seattle Genetics and Bristol-Myers Squibb Enter into Clinical Trial Agreement 81
Bristol-Myers Squibb Enters into Agreement with Ohio State University Comprehensive Cancer Center 82
IFM Therapeutics to Enter into Research Agreement with University of Michigan 83
Neon Therapeutics Enters into Agreement with Bristol-Myers Squibb 84
Bristol-Myers Squibb Enters into Research Agreement with UCLA 85
Bristol-Myers Squibb Enters into Research Agreement with Princeton University 86
Bristol-Myers Squibb Enters into Research Agreement with NCCN 87
Bristol-Myers Squibb Enters into Research Agreement with Sidney Kimmel Comprehensive Cancer Center 88
Bristol-Myers Squibb Enters into Research Agreement with Medical University of South Carolina 89
Bristol-Myers Squibb Enters into Agreement with uniQure 90
Rigel Enters into R&D Agreement with Bristol-Myers Squibb for TGF Beta Receptor Kinase Inhibitors 91
Bristol-Myers Squibb Enters into Agreement with Eli Lilly 92
Bristol-Myers Squibb and Seattle Genetics Enter into Agreement 93
Bristol-Myers Squibb Enters into Agreement with Five Prime Therapeutics for Opdivo and FPA008 94
OliPass Enters into Co-Development Agreement with Bristol-Myers Squibb 96
Bristol-Myers Squibb Enters into Agreement with Celgene 97
Bristol-Myers Squibb Forms Joint Venture with Allied Minds 98
Bristol-Myers Squibb Enters into Co-Development Agreement with Ono Pharma 99
Syngene International Extends R&D Agreement with Bristol-Myers Squibb 101
Pierre Fabre Enters into Co-Promotion Agreement with Bristol-Myers Squibb for Orencia 102
Evotec Extends Agreement with Padlock Therapeutics 103
Evotec Enters into Agreement with Padlock Therapeutics 104
Immuneering Enters Into Agreement With Bristol-Myers Squibb For New Medicines 105
AstraZeneca Enters Into Agreement With Bristol-Myers To Commercialize Dapagliflozin In Japan 106
Bristol-Myers Squibb And Samsung BioLogics Enter Into Agreement For Antibody Cancer Drug 107
Bristol-Myers Squibb Expands Co-Development Agreement With Simcere Pharma For Orencia 108
Ambrx Enters Into Co-Development Agreement With Bristol-Myers Squibb 110
Santaris Pharma Enters Into Agreement With Bristol-Myers Squibb For RNA-Targeted Medicines 111
Merck Serono Enters Into Co-Promotion Agreement With Bristol-Myers Squibb For Glucophage 112
PeptiDream Extends Discovery Agreement With Bristol-Myers Squibb 113
Valeant Pharma Enters into Option Agreement with Bristol-Myers Squibb 114
Vanderbilt University Enters Into Agreement With Bristol-Myers Squibb To Develop Drugs For Parkinson’s Disease 115
Prosetta Enters Into Co-Development Agreement With Bristol-Myers Squibb For Antiviral Drugs 116
Bristol-Myers Squibb Enters Into Co-Development Agreement With Emory University 117
Scripps Research Institute Enters Into Research Agreement With Bristol-Myers Squibb 118
Bristol-Myers Squibb Enters Into Co-Development Agreement With Tsinghua University 119
Bristol-Myers Squibb Enters Into Co-Development Agreement With Duke Translational Medicine Institute 120
Ensemble Therapeutics Extends Co-Development Agreement With Bristol-Myers Squibb 121
Bristol-Myers Squibb Enters Into Research Agreement With Gladstone Institutes 122
NeurOp Extends Drug Discovery Agreement With Bristol-Myers Squibb 123
Bristol-Myers Squibb Expands Co-Development Agreement With Simcere Pharma For BMS-795311 124
Dako Enters Into Co-Development Agreement With Bristol-Myers 125
Tranzyme Pharma Extends Co-Development Agreement With Bristol-Myers Squibb 126
Bristol-Myers Squibb Expands Co-Development Agreement With Ono Pharma 127
Bristol-Myers Squibb Enters Into Co-Development Agreement With Ono Pharma For ORENCIA 129
BAC Enters Into Co-Development Agreement With Bristol-Myers Squibb 131
GNS Healthcare Enters Into Co-Development Agreement With Bristol-Myers Squibb 132
Bristol-Myers Squibb Enters Into Co-Marketing Agreement With Matrix Labs 133
Hoffmann-La Roche Enters Into Co-Development Agreement With Bristol-Myers Squibb 134
Ayala Pharma Enters into Licensing Agreement with Bristol-Myers Squibb 135
Bristol-Myers Squibb and Halozyme Therapeutics to Enter into License Agreement 136
Biogen Enters into Licensing Agreement with Bristol-Myers Squibb 137
Roche to Enter into Licensing Agreement with Bristol-Myers Squibb 138
Merck Enters into Licensing Agreement with Bristol-Myers Squibb and Ono Pharma 139
Bristol-Myers Squibb to Enter into Licensing Agreement with PsiOxus Therapeutics 140
Bristol-Myers Squibb Enters into Licensing Agreement with Enterome 141
Bristol-Myers Squibb Enters into Licensing Agreement with Nitto Denko 142
Mylan Enters into Licensing Agreement with Medicines Patent Pool and Bristol-Myers Squibb Company for Daclatasvir 143
Biohaven Pharma Enters into Licensing Agreement with Bristol-Myers Squibb 144
Mylan Enters into Licensing Agreement with Medicines Patent Pool and Bristol-Myers Squibb Company 145
Eiger BioPharmaceuticals Enters into Licensing Agreement with Bristol-Myers Squibb 146
Bristol-Myers Squibb and Pfizer Enter into Licensing Agreement with Portola Pharma 147
Bristol-Myers Squibb Enters into Licensing Agreement with Kyorin Pharma 149
Zai Lab Enters into Licensing Agreement with Bristol-Myers Squibb 150
Bristol-Myers Squibb Enters into Option for Licensing Agreement with Bavarian Nordic 151
Bristol-Myers Squibb Enters into Licensing Agreement with California Institute for Biomedical Research 152
Cipla Enter into Licensing Agreement with Medicines Patent Pool and Bristol-Myers Squibb Company 153
Bristol-Myers Squibb Extends Licensing Agreement with CytomX Therapeutics 154
Five Prime Therapeutics Expand Licensing Agreement with Bristol-Myers Squibb 156
Medicines Patent Pool Extends Licensing Agreement With Bristol-Myers Squibb 158
Reckitt Benckiser Amends Licensing Agreement With Bristol-Myers Squibb For OTC Brands 159
Sanofi Enters into Licensing Agreement with Bristol-Myers Squibb 161
Bristol-Myers Squibb Enters into License Agreement with Ambrx 162
Lexicon Pharma Enters into Licensing Agreement with Bristol-Myers Squibb 163
MPP, Bristol-Myers Squibb and Laurus Labs Enter into Licensing Agreement For Daclatasvir 164
Cipla, Emcure Pharma, Hetero Drugs, Natco Pharma and Aurobindo Pharma Enter into Licensing Agreement with Medicines Patent Pool and Bristol-Myers Squibb 165
Medicines Patent Pool Enters into Licensing Agreement with Bristol-Myers Squibb For Daclatasvir 167
Bristol-Myers Squibb Enters into Licensing Agreement with Five Prime Therapeutics 168
Bristol-Myers Squibb Enters into Licensing Agreement with Kyorin Pharma 170
Bristol-Myers Squibb Enters into Licensing Agreement with QIMR Berghofer Medical Research Institute 171
Genmab Enters into Licensing Agreement with Bristol-Myers Squibb 172
Padlock Therapeutics Enters into Licensing Agreement with GlaxoSmithKline 173
Bristol-Myers Squibb Enters into Licensing Agreement with Novo Nordisk 174
Bristol-Myers Squibb Enters into Licensing Agreement with R-Pharm 175
Padlock Therapeutics Enters into Licensing Agreement with Scripps Research Institute 176
Bristol-Myers Squibb Enters Into Licensing Agreement With Kyowa Hakko Kirin For Coniel In China 177
PeptiDream Enters Into Licensing Agreement With Bristol-Myers Squibb For Peptide Discovery Platform System 178
PeptiDream Expands Agreement With Bristol-Myers Squibb For Drug Discovery 179
Medicines Company Enters Into Licensing Agreement With Bristol-Myers Squibb For Recothrom 180
Biocon Enters Into Option For Licensing Agreement With Bristol-Myers Squibb 182
Chiromics Enters Into Licensing Agreement With Bristol-Myers Squibb For Chemical Compounds 183
University Of Montreal Enters Into Licensing Agreement With Bristol-Myers Squibb 184
Bristol-Myers Squibb Enters Into Licensing Agreement With Vical For Antibodies 186
Summit Enters Into Licensing Agreement With Bristol-Myers Squibb For Seglin Technology 188
Genmab Enters Into Licensing Agreement With Cormorant Pharma For HuMax-IL8 189
Bristol-Myers Squibb Enters Into Licensing Agreement With Gilead Sciences 190
Bristol-Myers Squibb Enters Into Licensing Agreement With Innate Pharma For IPH2102 191
KineMed Extends Licensing Agreement With Bristol-Myers Squibb 193
iPierian Enters Into Licensing Agreement With Kyoto University 194
Kyoto University And iPS Academia Enter Into Licensing Agreement With iPierian 195
uniQure Raises USD38 Million in Private Placement of Shares 196
Panmira Pharmaceuticals Spin Out from Amira Pharmaceuticals 197
Inhibitex Files Registration Statement For Public Offering Of Securities For US$130 Million 198
Inhibitex Completes An Underwritten Public Offering For US$54.1 Million 199
Bristol-Myers Squibb Raises USD750 Million in Public Offering of 1.6% Notes Due 2019 201
Bristol-Myers Squibb Raises USD750 Million in Public Offering of 3.25% Notes Due 2027 203
Bristol-Myers Squibb Raises USD628 Million in Public Offering of 1.75% Notes Due 2035 205
Bristol-Myers Squibb Raises USD628 Million in Public Offering of 1% Notes Due 2025 206
Bristol-Myers Squibb Completes Public Offering Of Notes Due 2019 For US$500 Million 207
Bristol-Myers Squibb Completes Public Offering Of Notes Due 2023 For US$500 Million 209
Bristol-Myers Squibb Completes Public Offering Of Notes Due 2044 For US$500 Million 211
Bristol-Myers Squibb Completes Public Offering Of Senior Unsecured Notes Due 2017 For US$750 Million 213
Bristol-Myers Squibb Completes Public Offering Of 2% Senior Unsecured Notes Due 2022 For US$750 Million 215
Bristol-Myers Squibb Completes Public Offering Of 3.25% Senior Unsecured Notes Due 2042 For US$500 Million 217
Seattle Genetics to Acquire Pharma Manufacturing Facility from Bristol-Myers Squibb 219
SK Biotek to Acquire API Manufacturing Facility from Bristol-Myers Squibb 220
Reckitt Benckiser Exercises Option to Acquire OTC Products of Bristol-Myers Squibb for USD317 Million 221
ViiV Healthcare Acquires HIV R&D Assets of Bristol-Myers Squibb for up to USD835 Million 222
ViiV Healthcare Acquires HIV Research Assets of Bristol-Myers Squibb for USD620 Million 223
R-Pharm US Acquires Rights to IXEMPRA from Bristol-Myers Squibb 224
PharmaSwiss Acquires Trademarks and Intellectual Property of Certain Products from Bristol-Myers Squibb for USD61 Million 225
Bristol-Myers Squibb Reportedly To Sell Plavix And Avapro For US$750 Million 226
Emcure Pharma Acquires Rights of BiCNU Injection from Bristol-Myers Squibb 227
Synergy Pharma Acquires FV-100 From Bristol-Myers Squibb 228
Paladin Labs Completes Acquisition Of Tempra From Bristol-Myers Squibb 229
Bristol-Myers Squibb Acquires IFM Therapeutics 230
Bristol-Myers Squibb Acquires Cormorant Pharma 231
Bristol-Myers Squibb Acquires Padlock Therapeutic 232
Bristol-Myers Squibb Acquires Cardioxyl Pharma for up to USD2.1 Billion 233
Bristol-Myers Squibb Enters into Option to Acquire Promedior and PRM-151 for up to USD1.25 Billion 234
Bristol-Myers Squibb Acquires Flexus Biosciences for up to USD1.25 Billion 236
Bristol-Myers Squibb Enters into Option to Acquire Galecto Biotech and TD-139 237
Pfizer May Acquire Bristol-Myers Squibb 238
Bristol-Myers Squibb Acquires iPierian 239
AstraZeneca Completes Acquisition Of Remaining 50% Interest In Diabetes Joint Venture From Bristol-Myers Squibb For US$4.3 Billion 241
Bristol-Myers Rumored To Acquire Biogen Idec 243
Bristol-Myers Squibb Completes Acquisition Of Amylin Pharma For US$5.3 Billion 244
Bristol-Myers Squibb Completes Acquisition Of Inhibitex, Hepatitis C Drug Developer, For US$2.5 Billion 246
Bristol-Myers Squibb Acquires Amira Pharma For US$475 Million 249
Bristol-Myers Squibb Co, Key Competitors 251
Bristol-Myers Squibb Co, Key Employees 252
Bristol-Myers Squibb Co, Subsidiaries 254
Bristol-Myers Squibb Co, Joint Venture 260

★海外企業調査レポート[Bristol-Myers Squibb Co (BMY)-製薬・医療分野：企業M&A・提携分析]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Living Cell Technologies Ltd (LCT)：企業の財務・戦略的SWOT分析
    Living Cell Technologies Ltd (LCT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • First Quantum Minerals Ltd：戦略・SWOT・企業財務分析
    First Quantum Minerals Ltd - Strategy, SWOT and Corporate Finance Report Summary First Quantum Minerals Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Avita Medical Ltd (AVH)：企業の財務・戦略的SWOT分析
    Avita Medical Ltd (AVH) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • Finley Resources Inc：石油・ガス：M&Aディール及び事業提携情報
    Summary Finley Resources Inc (Finley) is an oil and gas company that owns, manages, operates and develops oil and gas properties. The company operates its oil and gas properties in the areas of Permian Basin, South Texas, East Texas, Mississippi, Barnett Shale, San Juan Basin, Alabama, Oklahoma and …
  • A. Menarini Industrie Farmaceutiche Riunite Srl-製薬・医療分野：企業M&A・提携分析
    Summary A. Menarini Industrie Farmaceutiche Riunite Srl (Menarini), formerly Farmacia Internazionale, is a biopharmaceutical company that undertakes the research, development and manufacture of several pharmaceutical products in various dosage forms. The company’s products portfolio is focused on a …
  • Sime Darby Berhad (SIME)-エネルギー分野：企業M&A・提携分析
    Summary Sime Darby Berhad (Sime Darby) is a trading and logistics company. It operates as a conglomerate that provides diversified products and services through its subsidiaries, affiliates, and joint ventures. The company cultivates oil palm, rubber, sugar cane, and cattle rearing and produces oil …
  • Lantern Pharma Inc：製薬・医療：M&Aディール及び事業提携情報
    Summary Lantern Pharma Inc (Lantern Pharma) is a clinical stage pharmaceutical company that discovers and develops therapies for various cancer types. The company’s pipeline products Irofulven-1 and Irofulven-2 are non-hormone, non-chemotherapy, next-generation DNA damage repair inhibitors. Its othe …
  • Clariant International Ltd (CLN)：企業の財務・戦略的SWOT分析
    Clariant International Ltd (CLN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • Office Depot, Inc.：戦略・SWOT・企業財務分析
    Office Depot, Inc. - Strategy, SWOT and Corporate Finance Report Summary Office Depot, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Therapeutic Solutions International Inc (TSOI)：医療機器：M&Aディール及び事業提携情報
    Summary Therapeutic Solutions International Inc (Therapeutic Solutions) is a pharmaceutical company that offers supplements. The company offers products such as DermalStilbene, NanoStilbene and ProJuvenol. Its ProJuvenol consists of anti-aging ingredients which helps for a healthy functionality for …
  • Banca Dello Stato Del Cantone Ticino
    Banca Dello Stato Del Cantone Ticino - Strategy, SWOT and Corporate Finance Report Summary Banca Dello Stato Del Cantone Ticino - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysi …
  • Carnival Corporation & plc：企業の戦略・SWOT・財務情報
    Carnival Corporation & plc - Strategy, SWOT and Corporate Finance Report Summary Carnival Corporation & plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Cellnovo Ltd-医療機器分野：企業M&A・提携分析
    Summary Cellnovo Ltd (Cellnovo), formerly Starbridge Systems Ltd is a provider of conventional diabetes care technology solutions. The company offers mobile diabetes management system, including an insulin patch pump, activity monitor, cellular-enabled wireless touchscreen handset with integrated bl …
  • Petrofac Ltd (PFC)：石油・ガス：M&Aディール及び事業提携情報
    Summary Petrofac Limited (Petrofac) is an oilfield services company that provides integrated services to production and processing industries. It designs and builds oil and gas facilities; operates, maintains and manages facilities on behalf of its customers and trains personnel. It also develops an …
  • Krka dd Novo Mesto (KRKG)：企業の財務・戦略的SWOT分析
    Summary Krka dd Novo Mesto (Krka) is a manufacturer and distributor of pharmaceutical products. The company provides prescription pharmaceuticals, non-prescription products, and animal health products. It offers prescription products for cardiovascular diseases, diseases of alimentary tract and meta …
  • SynCore Biotechnology Co Ltd：製薬・医療：M&Aディール及び事業提携情報
    Summary SynCore Biotechnology Co Ltd (SynCore), a subsidiary of Sinphar Pharmaceutical Co Ltd is a biopharmaceutial company that new drug by research and development management and integration of technology resources. The company’s pipeline products include SB01, SB02, SB03, SB04 and SB05; and diagn …
  • Adamis Pharmaceuticals Corp (ADMP)：医療機器：M&Aディール及び事業提携情報
    Summary Adamis Pharmaceuticals Corp (Adamis), formerly Cellegy Pharmaceuticals Inc, is a biopharmaceutical company that develops therapies in areas of respiratory disease and allergy. The company offers pipeline product, epinephrine pre-filled syringe is developed for anaphylactic reactions such as …
  • Fukoku Mutual Life Insurance Company
    Fukoku Mutual Life Insurance Company - Strategy, SWOT and Corporate Finance Report Summary Fukoku Mutual Life Insurance Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysi …
  • Systematic A/S：企業の戦略・SWOT・財務分析
    Systematic A/S - Strategy, SWOT and Corporate Finance Report Summary Systematic A/S - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • Samsung Biologics Co Ltd (207940)：製薬・医療：M&Aディール及び事業提携情報
    Summary Samsung Biologics Co Ltd (Samsung Biologics) is a biologics development and manufacturing company. The company’s business activities include process development, contract manufacturing, aseptic fill and finish and project management. Samsung Biologics cell culture development process include …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆